BioDelivery Sciences announces additions to its board
Timothy C. Tyson will join the BDSI Board of Directors as an independent member, and Mark A. Sirgo, BDSI's President and Chief Executive Officer and board member, will, in addition to his current positions, assume the role of Vice Chairman.
Mr. Tyson brings a strong, seasoned and independent voice to BDSI's board.
His corporate career spans over 30 years in the pharmaceutical industry, having in that time held senior executive level leadership positions as well as positions of responsibility overseeing key functional areas such as sales and marketing, manufacturing and supply, and research and development.
Mr. Tyson is currently Chairman and CEO of Avara Pharmaceutical Services and Chairman at Icagen Inc. and recently served as Chairman and CEO of Aptuit LLC.
From 2002 to 2008, Mr. Tyson served as Chief Operating Officer, President, and Chief Executive Officer of Valeant Pharmaceuticals International.
Prior to joining Valeant, Mr. Tyson ran multiple divisions of GlaxoSmithKline (GSK) and was a member of the corporate executive team.
During his fourteen-year tenure at GSK, he was President, Global Manufacturing and Supply, and ran Glaxo Dermatology and Cerenex Pharmaceuticals. He was also responsible for managing all sales and marketing for GlaxoWellcome's U.S. operations.
Mr. Tyson also held positions at Bristol Myers and Proctor & Gamble and served on active duty as an officer in the U.S. Army. He is a graduate of the United States Military Academy at West Point.
BDSI's Board of Directors has named Mark A. Sirgo as Vice Chairman in recognition of his leadership and contributions in building BDSI over the past twelve years.
Dr. Sirgo has served as President and Chief Executive Officer of BDSI since January 2005.
Dr. Sirgo has served on the BDSI Board since 2005 and previously served on the Board of Directors of Salix Pharmaceuticals Inc., from 2008 to 2015 where he was also Chairman of the Compensation Committee. ■